Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-Management and Provider Engagement: Protocol for a Feasibility Trial

Kidd, Sean A.; McKenzie, Kwame; Wang, Wei; Agrawal, Sacha; Voineskos, Aristotle N.

doi:10.2196/24736

Cited by 7 publications

(1 citation statement)

References 47 publications

(31 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… Note: All Features may not be discussed or covered. A4i* 48 , 49 Yes Yes + + + Kidd et al 2021 48 The A4i app aims to support by providing seven functionalities that include daily activities, passive data collection, peer support, and self-management. The goal of the study is to investigate the feasibility of A4i to supplement limited service.…”

Section: Resultsmentioning

confidence: 99%

Accessibility and availability of smartphone apps for schizophrenia

et al. 2022

View full text Add to dashboard Cite

App-based interventions have the potential to enhance access to and quality of care for patients with schizophrenia. However, less is known about the current state of schizophrenia apps in research and how those translate to publicly available apps. This study, therefore, aimed to review schizophrenia apps offered on marketplaces and research literature with a focus on accessibility and availability. A search of recent reviews, gray literature, PubMed, and Google Scholar was conducted in August 2022. A search of the U.S. Apple App Store and Google Play App Store was conducted in July 2022. All eligible studies and apps were systematically screened/reviewed. The academic research search produced 264 results; 60 eligible studies were identified. 51.7% of research apps were built on psychosis-specific platforms and 48.3% of research apps were built on non-specific platforms. 83.3% of research apps offered monitoring functionalities. Only nine apps, two designed on psychosis-specific platforms and seven on non-specific platforms were easily accessible. The search of app marketplaces uncovered 537 apps; only six eligible marketplace apps were identified. 83.3% of marketplace apps only offered psychoeducation. All marketplace apps lacked frequent updates with the average time since last update 1121 days. There are few clinically relevant apps accessible to patients on the commercial marketplaces. While research efforts are expanding, many research apps are unavailable today. Better translation of apps from research to the marketplace and a focus on sustainable interventions are important targets for the field.

show abstract

Section: Resultsmentioning

confidence: 99%

Accessibility and availability of smartphone apps for schizophrenia

et al. 2022

View full text Add to dashboard Cite

show abstract

App for independence: A feasibility randomized controlled trial of a digital health tool for schizophrenia spectrum disorders

Kidd,

D'Arcey,

Tackaberry-Giddens

et al. 2025

Schizophrenia Research

View full text Add to dashboard Cite

Perception of risk of relapse among patients with first episode and recurrent schizophrenia: a descriptive phenomenological study

Yu,

Sun,

Qin

et al. 2023

BMC Psychiatry

View full text Add to dashboard Cite

Background Patients suffering from schizophrenia are at a higher risk of relapse. The perception of the risk of relapse in patients is critical for relapse prevention. In the field of psychiatry, the study of risk perception of relapse has been neglected. Methods We carried out a qualitative study using a descriptive phenomenological approach. Data were collected at two psychiatric hospitals in China. In total, 22 patients with schizophrenia were recruited through purposive sampling. Face to face semi-structured in-depth interviews were conducted. Interview recordings were transcribed by the research team, and transcripts were analysed by two independent coders with Colaizzi’s descriptive analysis framework. The consolidated criteria for reporting qualitative research checklist were used for reporting. Results The data of first-episode patients yielded three themes: (i) lack of knowledge about disease recognition and medical treatment; (ii) overoptimistic estimation of the risk of relapse; (iii) perceived importance of treatment. For first-relapse patients : (i) initial awareness of relapse warning signs; (ii) lack of systematic and accurate assessment of disease information; (iii) the perception that drug withdrawal is related to relapse. Patients with multiple relapses: (i) susceptibility to relapse: confusion and powerlessness; (ii) the severity of relapse: suicidal thoughts and behavior; (iii) effects of perceived benefits and barriers of medication behaviour. Conclusions In schizophrenic patients with first-episode, first-relapse, and multiple relapses, there were dynamic changes in the perception of disease relapse risk and medication behaviour. Medical workers must improve risk awareness education. They should provide patients with scientific, accurate, and timely communication channels, and dynamically assess and manage the risk of relapse in various patients.

show abstract

Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-Management and Provider Engagement: Protocol for a Feasibility Trial

Cited by 7 publications

References 47 publications

Accessibility and availability of smartphone apps for schizophrenia

Accessibility and availability of smartphone apps for schizophrenia

App for independence: A feasibility randomized controlled trial of a digital health tool for schizophrenia spectrum disorders

Perception of risk of relapse among patients with first episode and recurrent schizophrenia: a descriptive phenomenological study

Contact Info

Product

Resources

About